I. Ordas, L. Eckmann, and M. Talamini, Ulcerative colitis, Lancet, vol.380, issue.9853, pp.1606-1625, 2012.

G. Meucci, M. Vecchi, and M. Astegiano, The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII)

, Am J Gastroenterol, vol.95, issue.2, pp.469-73, 2000.

J. Satsangi, M. S. Silverberg, and S. Vermeire, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications, Gut, vol.55, issue.6, pp.749-53, 2006.

K. B. Gecse and P. L. Lakatos, Ulcerative proctitis: an update on the pharmacotherapy and management, Expert Opin Pharmacother, vol.15, issue.11, pp.1565-73, 2014.

G. Pineton-de-chambrun, B. Tassy, and L. Kollen, The treatment of refractory ulcerative colitis, Best Pract Res Clin Gastroenterol, pp.49-57, 2018.

S. Ardizzone, G. Maconi, and A. Russo, Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis, Gut, vol.55, issue.1, pp.47-53, 2006.

R. Oren, N. Arber, and S. Odes, Methotrexate in chronic active ulcerative colitis: a doubleblind, randomized, Israeli multicenter trial, Gastroenterology, vol.110, issue.5, pp.1416-1437, 1996.

W. J. Sandborn, W. J. Tremaine, and K. W. Schroeder, A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis, Gastroenterology, vol.106, issue.6, pp.1429-1464, 1994.

I. C. Lawrance, A. Baird, and D. Lightower, Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis, Clin Gastroenterol Hepatol, vol.15, issue.8, pp.1248-55, 2017.

S. Bageacu, O. Coatmeur, and J. P. Lemaitre, Appendicectomy as a potential therapy for refractory ulcerative proctitis, Aliment Pharmacol Ther, vol.34, issue.2, pp.257-265, 2011.

T. Molnar, K. Farkas, and F. Nagy, Topically administered infliximab can work in ulcerative proctitis despite the ineffectiveness of intravenous induction therapy, Am J Gastroenterol, vol.104, issue.7, pp.1857-1865, 2009.

G. Bouguen, X. Roblin, and A. Bourreille, Infliximab for refractory ulcerative proctitis, Aliment Pharmacol Ther, vol.31, issue.11, pp.1178-85, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00552545

A. L. Mallet, G. Bouguen, and G. Conroy, Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. Dig Liver Dis, vol.49, pp.280-285, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01483854

P. Rutgeerts, W. J. Sandborn, and B. G. Feagan, Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, vol.353, issue.23, pp.2462-76, 2005.

W. J. Sandborn, B. G. Feagan, and C. Marano, Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, vol.146, issue.1, pp.85-95, 2014.

W. J. Sandborn, G. Van-assche, and W. Reinisch, Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis, Gastroenterology, vol.142, issue.2, pp.257-65, 2012.

R. W. Stidham, T. C. Lee, and P. D. Higgins, Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis, Aliment Pharmacol Ther, vol.39, issue.7, pp.660-71, 2014.

L. Peyrin-biroulet, W. Sandborn, and B. E. Sands, Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, Am J Gastroenterol, vol.110, issue.9, pp.1324-1362, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01191653

M. Ferrante, S. Vermeire, and H. Fidder, Long-term outcome after infliximab for refractory ulcerative colitis, J Crohns Colitis, vol.2, issue.3, pp.219-244, 2008.

E. Zampeli, M. Gizis, and S. I. Siakavellas, Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis, World J Gastrointest Pathophysiol, vol.5, issue.3, pp.1287-93, 2014.